United Therapeutics, Medtronic Stop Efforts to Develop Implantable System for Remodulin
June 23 2021 - 7:04AM
Dow Jones News
By Dave Sebastian
United Therapeutics Corp. and Medtronic Inc. have agreed to stop
further efforts to develop and commercialize the implantable system
for Remodulin, or ISR.
United Therapeutics Wednesday said the companies plan to wind
down the development program and to support patients already
enrolled in clinical studies of the ISR at United Therapeutics'
sole expense.
The end of the efforts comes after the evolution of treatment
options over the past few years, United Therapeutics said. There
weren't penalties associated with the termination of the
commercialization agreement, it added.
ISR has been developed in the past 12 years to deliver Remodulin
injection for patients with pulmonary arterial hypertension through
an implantable system developed by Medtronic. The two companies
struck a commercialization agreement for the U.S. in February
2019.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
June 23, 2021 06:51 ET (10:51 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Medtronic (NYSE:MDT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From Sep 2023 to Sep 2024